カテゴリ： GlobalData, アメリカ, 企業調査

Aimmune Therapeutics Inc (AIMT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aimmune Therapeutics Inc (AIMT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8299
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：61
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aimmune Therapeutics Inc (Aimmune) formerly Allergen Research Corp is a clinical-stage biopharmaceutical company that develops proprietary product candidates for the treatment of peanut and other food allergies. The company’s lead product candidate AR101 is used to treat the peanut allergy. Its pipeline program portfolio uses characterized oral desensitization immunotherapy (CODIT), a proprietary approach to oral immunotherapy. Aimmune discovers, develops and commercializes therapies related to food allergy. The company conducts academic research in partnership with various universities and other companies to develop novel product candidates. The company operates in the US and the UK. Aimmune is headquartered in Brisbane, California, the US.

Aimmune Therapeutics Inc (AIMT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Allergen Research Raises USD80 Million in Series B Financing 11
Allergen Research Raises US$17 Million In Series A Financing 13
Partnerships 14
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 14
Aimmune Therapeutics Enters Into Agreement With Nestle Health Science 15
Equity Offering 16
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 16
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 18
Aimmune Therapeutics Raises USD184 Million in IPO 19
Aimmune Therapeutics Inc – Key Competitors 20
Aimmune Therapeutics Inc – Key Employees 21
Aimmune Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Strategy And Business Planning 23
Jun 07, 2017: CoreRx and Aimmune Therapeutics Joint Expansion to Create Pharmaceutical Jobs and Increase the Base of Scientific Capabilities in the Tampa Bay Area 23
Financial Announcements 24
Aug 08, 2018: Aimmune Therapeutics announces second quarter 2018 financial results 24
May 08, 2018: Aimmune Therapeutics Announces First Quarter 2018 Financial Results 25
Mar 12, 2018: Aimmune Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 26
Nov 06, 2017: Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 28
Aug 08, 2017: Aimmune Therapeutics Announces Second Quarter 2017 Financial Results 30
May 08, 2017: Aimmune Therapeutics Announces First Quarter 2017 Financial Results 32
Mar 15, 2017: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results 33
Corporate Communications 35
Feb 14, 2018: Aimmune Therapeutics Names George du Toit and Wayne Shreffler to Scientific Advisory Board 35
Apr 13, 2017: Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer 36
Product News 37
06/07/2017: Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy 37
Clinical Trials 38
Mar 04, 2018: Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO 38
Feb 27, 2018: Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results at the AAAAI-WAO Joint Congress 40
Feb 20, 2018: Aimmune Therapeutics Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy 41
Feb 12, 2018: Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress 44
Jan 10, 2018: Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy 45
Jan 08, 2018: Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy 46
Nov 20, 2017: Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 47
Oct 31, 2017: Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial 48
Oct 19, 2017: Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings 50
Aug 08, 2017: Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy 51
Jul 05, 2017: Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy 52
Jun 20, 2017: Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress 53
Jun 15, 2017: Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 54
Jun 12, 2017: Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy 55
May 11, 2017: Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy 56
Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 57
Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 59
Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Allergen Research Raises USD80 Million in Series B Financing 11
Allergen Research Raises US$17 Million In Series A Financing 13
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 14
Aimmune Therapeutics Enters Into Agreement With Nestle Health Science 15
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 16
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 18
Aimmune Therapeutics Raises USD184 Million in IPO 19
Aimmune Therapeutics Inc, Key Competitors 20
Aimmune Therapeutics Inc, Key Employees 21
Aimmune Therapeutics Inc, Other Locations 22
Aimmune Therapeutics Inc, Subsidiaries 22

List of Figures
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aimmune Therapeutics Inc (AIMT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Gestamp Renewable Industries：電力：M&Aディール及び事業提携情報
    Summary Gestamp Renewable Industries, a subsidiary of Corporacion Gestamp SL, is a renewable energy service provider. The company offers development, promotion, construction and operation of electric generation power plants from biomass. It offers production, logistics, packaging, generation, design …
  • Northern Ireland Electricity Networks Ltd：企業の戦略的SWOT分析
    Northern Ireland Electricity Networks Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Cameco Corporation：企業の戦略・SWOT・財務分析
    Cameco Corporation - Strategy, SWOT and Corporate Finance Report Summary Cameco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Macquarie Group Ltd：企業の戦略・SWOT・財務情報
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Recipharm AB (RECI B)：医療機器：M&Aディール及び事業提携情報
    Summary Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The organization's manufacturing segment provides contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, soli …
  • Olin Corporation：企業の戦略・SWOT・財務分析
    Olin Corporation - Strategy, SWOT and Corporate Finance Report Summary Olin Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sangui BioTech International Inc (SGBI)：企業の財務・戦略的SWOT分析
    Sangui BioTech International Inc (SGBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • MeVis Medical Solutions AG (M3V)-医療機器分野：企業M&A・提携分析
    Summary MeVis Medical Solutions AG (MMS AG) is a medical technology company. It develops and offers medical imaging solutions for digital computer-aided medical imaging. The software solutions are used in screening, diagnostics, therapy and intervention planning for breast, lung, colon, and prostate …
  • Nimir Industrial Chemical Ltd (NICL)：企業の財務・戦略的SWOT分析
    Summary Nimir Industrial Chemical Ltd (NICL) is a chemical company that manufactures and distributes oleo chemicals and chlor alkali. The company offers products such as stearic acid, soap noodles, glycerin, caustic soda, sodium hypochlorite, and hydrochloric acid, among others. It also provides raw …
  • EpiVax Inc-製薬・医療分野：企業M&A・提携分析
    Summary EpiVax Inc (EpiVax) is an immunology company which develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear se …
  • WorleyParsons Limited：企業の戦略・SWOT・財務分析
    WorleyParsons Limited - Strategy, SWOT and Corporate Finance Report Summary WorleyParsons Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bunge North America, Inc.：戦略・SWOT・企業財務分析
    Bunge North America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bunge North America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Investor AB (INVE B)：企業の財務・戦略的SWOT分析
    Investor AB (INVE B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Jungheinrich AG：企業の戦略・SWOT・財務情報
    Jungheinrich AG - Strategy, SWOT and Corporate Finance Report Summary Jungheinrich AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • DCP Midstream Partners, LP：企業の戦略・SWOT・財務情報
    DCP Midstream Partners, LP - Strategy, SWOT and Corporate Finance Report Summary DCP Midstream Partners, LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Blue Energy Ltd (BUL)：企業の財務・戦略的SWOT分析
    Summary Blue Energy Ltd (BEL) is an oil and gas company that provides exploration and development services. The company provides exploration and production of coal seam gas and conventional oil, and gas resources in Australia. Its projects portfolio includes Carpentaria basin, Bowen basin, galilee b …
  • Siemens Medical Solutions USA Inc：企業のM&A・事業提携・投資動向
    Siemens Medical Solutions USA Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Siemens Medical Solutions USA Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Syngene International Ltd (SYNGENE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a clinical research and manufacturing organisation. The organisation offers research, development and manufacturing programs. It provides discovery chemistry, discovery biology, large molecule development, safety assessment, …
  • WellCare Health Plans Inc (WCG)：企業の財務・戦略的SWOT分析
    WellCare Health Plans Inc (WCG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Oncodesign SA (ALONC)：企業の財務・戦略的SWOT分析
    Summary Oncodesign SA (Oncodesign) is a biopharmaceutical company, specializing in precision medicine offers drug discovery and pharmacological evaluation services for cancer. Its service offerings include integrated drug discovery; metabolic and pharmacokinetic characteristics of chemical and biolo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆